HONG KONG, May 21, 2025 – We are thrilled to announce that today, May 21, 2025, Eagle IP celebrates its 20th anniversary, marking two decades of dedication to client success and innovation in patent law. Founded on May 21, 2005 by Dr. Jacqueline Lui (Jackie), the firm has grown from its humble beginnings into a respected name in the industry.

In a recent team celebration, Jackie, the firm’s founder, shared her reflections on Eagle IP’s journey. “Starting Eagle IP was a leap of faith driven by my commitment to my clients and their patent portfolios,” she said. “Transferring two significant portfolios laid the foundation for the beginnings of the firm and paved the way towards our success. I’m grateful for the perseverance that carried us through tough times. Our CPR culture—caring, professional, and responsive—has defined who we are and will guide us forward.”

The anniversary event highlighted the firm’s strong culture, with team members who have been with the firm for over a decade sharing memories of growth under Jackie’s leadership.

Jennifer Che, current President and Managing Director who “took the baton” of Eagle IP leadership last year from Jackie, expressed her commitment to upholding these values while driving expansion, noting the firm’s increasing client base and active participation in global conferences.

Eagle IP looks to the future with optimism, dedicated to maintaining its high standards, fostering continuous learning, and building stronger team relationships. Jackie and her husband HC Lui emphasized the power of teamwork, assuring continued support as the firm embarks on its next chapter.

A huge THANK YOU to all our clients, mentors, and colleagues who have supported us through the years.

Our Past Events

Recommended Insights

New Policies to Promote Importation of Innovative Drugs

8 November 2018
At the April 12, 2018 executive meeting of the State Council in China, Premier Mr. Li Keqiang indicated the government’s desire to increase China’s access to innovative drugs. To achieve this, the government would encourage importation of innovative drugs into China by streamlining the regulatory pathway, enhancing IP protection, and lowering the cost of medicine. […]

Do Promotional Marketing Materials Constitute an “Offer for Sale” under Chinese Patent Law? Bayer IP GmbH v. Nanjing Hang Seng Pharmaceutical

12 December 2023
Bayer's blockbuster drug Rivaroxaban has seen its share of patent litigations in China, several of which are big enough to be listed as Top 10 IP cases or 50 Representative IP cases. We summarized an invalidation case back in 2020 where all of Bayer’s claims directed towards the compound were upheld. Recently, another Rivaroxaban case […]

China Releases Draft Implementation Guidelines for the Drug Administration Law

2 June 2022
The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]

Stay Ahead: Getting a Chinese Patent in Three Months?

23 April 2024
The China National Intellectual Property Administration (CNIPA) has announced a significant development in the realm of patent prosecution: the initiation of the "PPH Improvement Initiative" in collaboration with key patent offices from the United States, Europe, Japan, and South Korea. This initiative aims to elevate the user experience of the Patent Prosecution Highway (PPH) by […]
Top crossarrow-right